Oramed begins patient enrollment in US Phase IIa trial of diabetes drug ORMD-0801
The prospective, randomized, double-blind, placebo-controlled Phase IIa trial is designed to enroll up about 24 patients with type 1 diabetes in-clinic for ten days. During the trial, patients